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introDuction
Radiotherapy alone or in multimodality approaches is 
applied in 45–60% of all cancer patients, but despite tech-
nical innovations approximately only 50% are cured (1 and 
references therein). At present, the most commonly used 
mode of radiotherapy with high energy linear accelera-
tors is using an externally generated photon beam directed 
towards the exact delineated tumor site. Other forms of 
radiation include radiotherapy with charged particles 
such as electron beams, protons and heavier charged ions 
such as 12C. Of these, proton radiotherapy is becoming a 
reasonable alternative worldwide.2–4 Stratification towards 
a specific quality of ionizing radiation is primarily based on 
clinical parameters, not taking any biological aspects into 
consideration.
The major difference between photon- and particular 
proton- based radiotherapy is the spatial distribution of 
energy deposition. Photon beams have the highest dose 
deposition close to the entrance surface and continuously 
deposit dose at the whole path throughout the tissue. 
Generally, this involves healthy tissue being co- irradiated 
proximal and distal to the target volume. In contrast, proton 
beams commonly deposit a lower dose in the entry field, 
and maximum dose deposition occurs within the so- called 
Bragg peak at a depth defined by the velocity of the applied 
protons. Behind this Bragg peak region—or spread- out 
Bragg peak (SOBP) in clinical applications—no significant 
dose is deposited5 (Figure 1). Thereby, a reduced exposure 
of dose- limiting organs- at- risk (OARs), e.g. the brain stem, 
the optical nerve and the oral cavity, to low and interme-
diate doses of ionizing radiation is achieved by proton 
radiotherapy.6,7 Eventually, this will result in a reduced risk 
of normal tissue toxicities and secondary malignancies in 
these co- irradiated organs close to treated entities such as 
skull- based and intracranial tumors, uveal melanoma and 
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abstract
Clinical parameters and empirical evidence are the primary determinants for current treatment planning in radiation 
oncology. Personalized medicine in radiation oncology is only at the very beginning to take the genetic background of 
a tumor entity into consideration to define an individual treatment regimen, the total dose or the combination with a 
specific anticancer agent. Likewise, stratification of patients towards proton radiotherapy is linked to its physical advan-
tageous energy deposition at the tumor site with minimal healthy tissue being co- irradiated distal to the target volume. 
Hence, the fact that photon and proton irradiation also induce different qualities of DNA damages, which require differ-
ential DNA damage repair mechanisms has been completely neglected so far. These subtle differences could be effi-
ciently exploited in a personalized treatment approach and could be integrated into personalized treatment planning. 
A differential requirement of the two major DNA double- strand break repair pathways, homologous recombination and 
non- homologous end joining, was recently identified in response to proton and photon irradiation, respectively, and 
subsequently influence the mode of ionizing radiation- induced cell death and susceptibility of tumor cells with defects 
in DNA repair machineries to either quality of ionizing radiation.
This review focuses on the differential DNA- damage responses and subsequent biological processes induced by photon 
and proton irradiation in dependence of the genetic background and discusses their impact on the unicellular level and 
in the tumor microenvironment and their implications for combined treatment modalities.
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Progressive cognitive decline and impaired brain develop-
ment represent major risk factors after conventional cranial 
radiotherapy in pediatric patients. Thus, particle radiotherapy 
represents an ideal treatment modality to reduce these side- effects 
in the central nervous system in pediatric tumor patients.11,12
Preclinical in vitro and in vivo experiments suggest an enhanced 
potency for proton- vs photon- irradiation. This enhanced rela-
tive biological effectiveness (RBE) is accounted for by the generic 
RBE value of 1.1 used in the clinics. In general, the RBE depends 
on the linear energy transfer (LET), the radiation dose, the 
number of fractions applied, the dose range and the biological 
system or end point analyzed.
The RBE is the ratio of the dose of high- energy photons, e.g. 60Co 
γ-rays or linear accelerator generated X- rays, relative to that of 
protons required to produce the same biological response. This 
effect is generally considered to be relatively small for protons, 
and a generic RBE of 1.1 has been used throughout its history 
for dose specification with virtually no exceptions being made 
for the dose/fraction, position in the SOBP, initial beam energy, 
or the tissue being irradiated. The global use of an RBE value of 
1.1, i.e. a 10% higher biologic effectiveness of protons compared 
to photons, is based primarily on radiobiology experiments 
conducted in the 70’s and 80’s.13 However, the LET varies along a 
clinically relevant SOBP. For example, in case of a 62 MeV proton 
beam with a 10 mm SOBP centered at 25 mm depth, the LET 
ranges from approximately 1 keV/μm at the entrance field, to 4 
keV in the SOBP and reaches up to 25 keV/μm at the Bragg Peak. 
Eventually, several groups also demonstrated a varying RBE 
depending on the position cells and tissue were placed within 
the SOBP, with the highest RBE when cells were positioned 
in the Bragg peak area.14,15 This corresponds to enhanced cell 
killing per gray of irradiation as LET increases. These consid-
erations result in “LET painting” as an approach to shift distal 
end, high LET and thus high RBE irradiation away from critical 
organs into the tumor treatment volume.16–18 However, the clin-
ical decision at the leading proton facility, the Harvard Cyclotron 
Laboratory, was made to proceed with a RBE factor of 1.1 as the 
basis of treating patients.19 Subsequent clinical data of the last 
20–30 years have though confirmed the usefulness of the factor 
of 1.1 in clinical practice.
Based on the improved experimental systems, the increased 
knowledge gained during the last decades on ionizing radiation- 
induced biological responses and the increasing amount of 
proton radiotherapy centers with integrated radiobiological 
research facilities, molecular and cellular- oriented studies 
are now routinely performed to investigate differential stress 
responses and differential damage profiles induced by proton 
vs photon irradiation. Thereby, the RBE will be characterized 
not only in relation to the differential energies but also from 
the differential processes induced on the molecular, cellular and 
(patho-) physiological level. These putative differences could 
eventually be important for different treatment strategies (e.g. as 
part of combined treatment modalities) and for patient stratifi-
cation, challenge the use of a generic RBE and asks to integrate 
biological parameters into treatment planning.20,21
Recent insights from our own and other research laboratories 
indicate that differential qualities of DNA damage and subse-
quently differential DNA- damage responses (DDR) are induced 
in response to photon and proton irradiation. These differential 
“biologies” may be important for the concept of personalized 
medicine in radiotherapy. Nowadays, treatment planning of an 
individual patient primarily takes clinical and physical param-
eters into account. Eventually, stratification towards proton vs 
photon irradiation might also take these differential ”biologies” 
on the personalized level into consideration.
Ionizing radiation induced cytotoxicity on the 
individually targeted cell
Ionizing radiation induces DNA double- strand breaks (DNA 
DSB), which represent the major cytotoxic insult. These DSBs are 
to a large extent correctly repaired by the two major DNA DSB 
repair pathways, namely the error- free homologous recombina-
tion repair (HRR) and the more error- prone non- homologous 
end joining (NHEJ) process.22 NHEJ is quantitatively highly effi-
cient to repair most of the DSBs throughout the cell. However, 
the quality of repair steadily decreases with increasing amounts 
of DNA DSBs and NHEJ- mediated chromosomal translocations 
might even lead to toxic chromosomal aberrations.23 In an initial 
step, Ku70/80 heterodimers are formed at the broken end, which 
leads to the recruitment of DNA- PKcs, followed by processing 
of the “dirty” ends by specific DNA nucleases and polymerases 
and religation of the broken strands by the XRCC4- DNA Ligase 
IV complex.
Figure 1. Differential depth dose distributions of photons ver-
sus protons. Photon beams have the highest dose deposition 
close to the entrance surface and continuously deposit dose 
at the whole path throughout the tissue. In contrast, proton 
beams deposit a lower dose in the entry field, and maximum 
dose deposition occurs within the so- called Bragg peak or 
SOBP in clinical applications. The reduced volume of healthy 
tissue exposed to intermediate and low doses of proton radi-
otherapy results in a reduced co- irradiation of dose- limiting 
OAR. OARs, organs- at- risk; SOBP, spread- out Bragg peak.
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In contrast to NHEJ, HRR is an error- free process. Following 
MRN- and CtIP- dependent 3`−5`DNA resection, the single- 
stranded DNA overhangs are stabilized by the heterotrimeric 
ssDNA- binding complex RPA.24 With the help of the tumor 
suppressor BRAC2, RPA is then replaced by RAD51 to form 
RAD51 nucleoprotein filaments and Holliday junctions (HJ) 
with complementary sequences on the adjacent sister chromatid. 
Eventually, these structures are resolved by several HJ processing 
factors on completion of DNA polymerase- dependent error- free 
rewriting of the damaged DNA sites.25–27
Incorrectly repaired DNA DSB might lead to reciprocal translo-
cations of chromosomal regions. These newly rearranged, dupli-
cated but still monocentric chromosomes can still be segregated 
into the two surviving daughter cells following mitosis. On the 
other hand, most cells with dicentric chromosomes undergo cell 
death. These chromosomal aberrations are formed due to incor-
rect DNA DSB repair and form unresolvable anaphase bridges 
during chromosomal segregation in M- phase and activate a 
mitotic checkpoint. Cells with unresolved, prolonged mitotic 
checkpoints or cells with extended chromosomal aberrations, 
which managed to slip into the next cell cycle, will eventu-
ally undergo mitotic catastrophe in the initial or in one of the 
following cell cycles, respectively. Overall, these cells undergo 
cell death as a direct consequence of ionizing radiation- induced 
DNA damage, incomplete DNA damage repair and the formation 
of chromosomal aberrations, which can not be properly segre-
gated into the two daughter cells (Figure 2).
Cellular hypersensitivity towards proton irradiation 
in dependence of the genetic background
As part of an RBE- oriented non- small cell lung cancer (NSCLC) 
cell line screen, hypersensitivity to proton irradiation could be 
linked to defects in a specific DNA damage repair machinery.28 
Subsequently, the research group of H. Willers (Massachusetts 
General Hospital, Boston) could identify specific alterations of 
the Fanconi- Anemia (FA)/BRCA- replication- coupled HRR 
pathway of DNA repair in three out of 17 cell lines with an 
increased RBE.28 For these comparative experiments, lung cancer 
cell lines were positioned at the mid- SOBP of a clinical proton 
beam (235 MeV). Control experiments with genetically modi-
fied lung cancer cells validated the relevance of this pathway, 
and supported the hypothesis of specific proton hypersensitivity 
due to HRR- defects (RBE- shift from 1.1 to 1.39 in dependence 
of FANCD2- expression level). The same group performed addi-
tional control experiments on two downstream elements of the 
FA/BRCA- pathway, namely Slx4(FancP) and Mus81.29 Slx4- and 
Mus81- deficient cells were also hypersensitive towards proton 
irradiation in comparison to their isogenic wildtype counter-
part cells (RBE- shift from 1.1 to 1.29 in dependence of Mus81- 
mutational status).
Figure 2. Ionizing radiation induced cytotoxicity on the individually targeted cell level and via the tumor microenvironment. 
Incorrectly repaired DNA double strand breaks might lead to chromosomes containing reciprocal translocations of chromosomal 
regions. These monocentric chromosomes can still be segregated into the two surviving daughter cells following mitosis. On the 
other hand, most cells with dicentric chromosomes (shown) will undergo cell death. These chromosomal aberrations activate a 
mitotic checkpoint and will eventually undergo mitotic catastrophe in the initial or in one of the following cell cycles, respectively 
(direct cytotoxicity). Acentric DNA fragments (shown) are at the same time encapsulated into micronuclei, which are often leaky, 
and subsequently release small DNA fragments into the cytosol. These small DNA fragments stimulate the expression and secre-
tion of imunostimulatory cytokines via the cGAS- STING pathway, and are now regarded as co- factors and starting point for ion-
izing radiation- induced immunogenic cell death. Immunogenic cell death contributes to tumor control acting also against tumor 
cells (indirect cytotoxicity), which initially survived direct targeting by ionizing radiation.
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In parallel to this genomic profiling approach, hypersensi-
tivity towards proton irradiation in HRR- deficient cells has 
been corroborated in several established cancer cell lines. 
PEO1- ovarian carcinoma cells that are lacking intact BRCA2- 
expression but are otherwise genetically identical to PEO4- 
ovarian carcinoma cells, were hypersensitive towards proton in 
comparison to photon irradiation. Likewise, clonogenic survival 
of A549 NSCLC cells that were depleted of Rad51, was strongly 
reduced in response to proton irradiation in comparison to 
control cells that were irradiated with either quality of ionizing 
radiation.30 Downregulation of Rad51 also resulted in delayed 
γH2AX- foci repair kinetics (see below). These experiments 
were also performed with cells positioned in the middle of the 
SOBP and with a clinical proton beam. Of note, besides HHR 
and NHEJ as major DNA DSB repair machineries, additional 
DNA DSB damage repair pathways exist, which also co- deter-
mine the cellular response to ionizing radiation. However, at this 
stage and due to the lack of defined comparative experiments, we 
cannot estimate, e.g. the impact of alternative NHEJ (Alt- NHEJ) 
to a putative shift of the RBE and thus a differential radiation 
response to proton vs photon radiation.
A set of well- characterized chinese hamster ovary (CHO) cell 
lines was traditionally used in radiobiology to define the involve-
ment of the different DNA DSB repair machineries for photon 
irradiation- induced DNA damage. These CHO cell lines have 
defined defects in different DNA repair machineries and are 
now also very suitable to characterize subtles differences in the 
cellular response to different qualities of ionizing radiation.31–33
In comparison to the corresponding wildtype cells, an increased 
RBE was determined in the HRR- defective cells, indicating 
hypersensitivity of HRR- deficient cells towards proton irradia-
tion (RBE37%: 1.54 ± 0.10 and RBE10%: 1.44 ± 0.06 HRR- deficient 
cells vs RBE37%: 1.25 ± 0.05 and RBE10%: 1.29 ± 0.04 wildtype 
cells).The RBE (survival fraction as end point) was determined 
with cell positioned in the middle of the SOBP, with a length of 
5 cm and maximum proton energy of 138 MeV. NHEJ- defective 
cells (XR- C1; DNA- PKcs- deficient CHO cells) were overall more 
sensitive to both types of ionizing radiation in comparison to 
wildtype cells. However, no hypersensitivity towards proton 
irradiation was identified in the NHEJ- defective cells.34 Of note, 
differential patterns of chromosomal aberrations, in particular 
with an increased amount of smaller fragments, were identified 
in response to proton and photon irradiation (see below).
The HRR status of tumors predicts treatment sensitivity to several 
anticancer agents such as cisplatinum and taxanes. Furthermore, 
the concept of synthetic lethality was developed based on the 
identification of BRCA1/BRCA2- mutations leading to enhanced 
sensitivity to PARP- inhibitors.35 Large- scale next generation 
sequencing studies on molecular profiling of solid tumors 
beyond BRCA1/2 suggest that more than 15% carry mutations 
in HRR.36 Based on the enhanced sensitivity of tumor cells with 
HRR- mutations to proton irradiation and preference of proton- 
induced DNA damage to be repaired by HRR, stratification of 
patients towards proton vs photon radiotherapy should also take 
the mutational status of the tumor into consideration.
Damages at the molecular DNA level and DNA damage- related 
signaling should be determined to detect and quantify ionizing 
radiation- induced DSBs and repair of DNA DSBs over time. 
However, for the sake of convenience, most studies only focus 
on the formation and processing of γH2AX- foci in response to 
ionizing radiation, which are easily detectable. As part of the 
initial DNA damage response to DSB, the histone variant H2AX 
are posttranslationally phosphorylated in order to mark the site 
of the DNA DSB and to initiate DNA DSB repair. γH2AX- foci 
detection has now become a powerful method to quantify DNA 
DSBs induced by ionizing radiation. Phosphorylated H2AX 
was originally named γH2AX as it was first observed in γ-ray- 
exposed cells.37 Clusters of γH2AX molecules at the site of DNA 
breaks allow detection and quantification of individual DSBs by 
using γH2AX- oriented antibodies.38 Interestingly, the specific 
shape and the kinetics of γH2AX- foci formation and processing 
(incl. 53BP1- foci, which also accumulate at the site of DNA 
damage) might be used to mark repair- defective and proton irra-
diation hypersensitive tumors. Using these foci as biomarkers 
was suggested by the research group of H. Willers, who identified 
an increased size of 53 BP-1 foci in FA/BRCA- pathway- deficient 
tumor cells, in particular in response to proton irradiation. These 
large foci might be due to an increased complexity of clustered 
DNA damage in response to proton irradiation.28,39 Since the 
FA/BRCA- pathway is specifically involved in replication fork 
maintenance and repair, increase of foci sizes might result from 
impaired repair of replication forks that collide with clustered 
proton damages.
In the genetically defined CHO cell system no significant 
quantitative differences in the initial amount of DNA DSBs 
were observed in cells irradiated by the two types of irradia-
tion. However, elevated numbers of residual γH2AX- foci were 
detected in the HR- deficient cells after proton irradiation, 
indicative for delayed repair kinetics after proton irradiation. 
Cells were always irradiated in the middle of the SOBP in order 
avoid additional LET- depending influences across the SOBP. 
These results support the notion of a differential quality of DNA 
damage induced by proton vs photon irradiation. Further-
more, the qualitative difference on the level of the DNA damage 
response correlate with the quantitative clonogenic cell survival 
data and indicate a specific requirement for FA/HRR for potent 
DNA DSB repair in response to proton irradiation.
Recently, DNA DSB repair kinetics were investigated in response 
to photon and proton irradiation analyzing formation and 
removal of γH2AX and 53BP1- foci in murine prostate adeno-
carcinoma and murine embryonic fibroblast.40 In this study, cells 
were exposed to the same dose but irradiated at different posi-
tions with the proton beam (plateau and Bragg Peak). A 105.5 
MeV proton beam, was decelerated by a range shifter to approx-
imately 31 MeV within the Bragg- peak. For the plateau proton 
set- up, a higher energy of 220 MeV was used to ensure that the 
proton beam was still in the plateau zone when reaching the cells 
after crossing the same range shifter. Consequently, the cells were 
hit by a proton beam with 187 MeV. Again, similar amounts of 
foci were induced in response to photon and proton irradiation, 
but foci- induction, processing and removal was delayed in cells 
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irradiated in the Bragg peak of the proton beam. Furthermore, 
the shape of Bragg peak- induced foci was more irregular and 
larger than foci induced by photon and plateau- protons. These 
differential characteristics might be linked to overlapping DNA 
lesions in close proximity to another, also resulting in more 
complex, clustered lesions. Such lesions were as also observed on 
irradiation with high LET charged particles, which also require 
more time for repair and eventually differential DNA repair 
machineries.41,42 An increased complexity of proton- induced 
DNA damage with more persistent foci but only at the distal 
end of a SOBP was also demonstrated in detailed comparative 
irradiation studies with cells positioned along a modulated 
SOBP proton beam43 confirming the overall low- LET- quality of 
proton exposure but with increased LET towards the distal end. 
Again, these qualitative DNA- damage- oriented results on the 
unicellular level correlate with differential RBEs (clonogenic cell 
survival) when cells are irradiated at different positions within a 
SOBP in vitro44,45 and in vivo.14
Overall, these preclinical results link a putative differential 
quality of DNA damage in response to proton vs photon irra-
diation to a hypersensitivity to proton irradiation and increased 
cytotoxicity on the unicellular level.
Hypersensitivity towards proton irradiation in the 
tumor microenvironment
Ionizing radiation may induce different modes of cell death, 
which are primarily linked to the origin of the targeted cells 
and their differentiation status. Besides mitotic catastrophe (see 
above), also enhanced cell apoptosis was identified after low 
LET proton irradiation in comparison to photon irradiation.46 
Recently, the irradiation- induced response of the immune system 
and its related induction of immunogenic cell death (ICD) has 
gained of interest, and—even though still to be proven—proton 
and photon- irradiation might induce different levels of ICD, 
which again might be linked to the status of the two major DNA 
DSB repair machineries.
As indicated above, acentric fragments have long been regarded 
as waste by- products of chromosomal aberrations and less rele-
vant for the direct cytotoxic potency of ionizing radiation. These 
small acentric fragments are encapsulated into micronuclei (MN) 
and these MN are actually used as biomarkers for the induction 
of mitotic catastrophe. Interestingly though, these MNs and the 
encapsulated small DNA fragments are now regarded as starting 
point of co- stimulatory factors for ionizing radiation- induced 
ICD.
Irradiation activates an anti tumor immune response through 
the release of danger signals and inflammatory cytokines thereby 
promoting dendritic cells to cross- present released antigens to 
T cells.47 A thereby triggered cytotoxic T cell response might be 
directed toward the primary irradiated tumor, but might also acts 
against non- irradiated metastasis via an abscopal effect, directed 
against non- irradiated lesions. Interestingly though, the acen-
tric DNA fragments, classified as by- products of the incorrectly 
repaired chromosomes, act as initial co- factors for the activation 
of this so called cancer- immunity cycle in response to irradiation. 
While compartmentalization of the cell separates nuclear- 
located chromosomes from the cytosol and prevents sensing 
of DNA in the cytosol, rupture of micronuclei gives access of 
cytosolic proteins to DNA. Likewise, small DNA fragments may 
also leak out from MN into the cytosol. DNA fragments trigger 
the formation of the second messenger cGMP- AMP (cGAMP) 
by the cytoplasmic protein GMP- AMP synthase (cGAS), and 
cGAMP activates the Stimulator of Interferon Genes (STING)- 
dependent signal transduction cascade leading to the expression 
and secretion of pro- inflammatory cytokines such as interferone 
α and β48,49. These cytokines contribute to tumor recruitment 
and activation of Batf3- lineage dendritic cells, which are respon-
sible for correct priming of T- cells as part of the cancer immunity 
cycle47 (Figure 2).
As such, incorrectly repaired ionizing radiation- induced DNA 
damage results in DNA- insults (dicentric chromosomes) directly 
acting in a cytotoxic way on the unicellular level and may indi-
rectly (acentric fragments) stimulate an immune- mediated 
tumor- oriented toxic microenvironment. Both mechanisms are 
induced in response to different qualities of ionizing radiation, 
but to different extents and in dependence of different genetic 
backgrounds.
A few studies have so far directly compared the regulation of 
immune- stimulatory factors and surface molecules in response 
to different qualities of ionizing radiation that are required for 
successful ionizing radiation- triggered ICD. A common signa-
ture of surface molecules involved in immune recognition, 
tumor- associated antigens and calreticulin surface expres-
sion was observed in multiple tumor cell lines in response 
to photon and proton irradiation, relevant for successful 
cytotoxic T- lymphocyte mediated cell killing.50 On the other 
hand, inflammatory factors such as IL6, IL8 and CXCL12 were 
generally less extensively upregulated by proton irradiation in 
comparison to photon irradiation.51 Of interest, proton irradi-
ation in particular at higher dosages results in increased rates of 
micronuclei formation in comparison to photon irradiation as 
characterized in thyroid follicular cells (0–12 Gy) and human 
peripheral blood lymphocytes (2–4 Gy).46,52 Since micronuclei 
encapsulate small DNA fragments, an enhanced rate of micro-
nuclei formation may also correlate with a higher rate of acen-
tric and small DNA fragments generated in response to proton 
irradiation.34
The generation of small DNA fragments in response to irradi-
ation is also determined by an intact DNA damage response. 
Interestingly, micronuclei formation and cGAS- STING activa-
tion was specifically increased in a BRCA2- and thus HR- defi-
cient background in tumor cells as part of replicative stress even 
in absence of irradiation- induced DNA damage.53 Given the 
hypersensitivity of HR- defective tumor cells to proton irradia-
tion on the unicellular level, it will be of interest to determine 
activation of the cancer immunity cycle and induction of ICD in 
tumors derived from HR- intact and HR- defective tumor cells in 
response to proton irradiation but in an otherwise intact tumor 
microenvironment.
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Combined treatment modalities with HRR-
interfering agents
A combined treatment modality with specific inhibitors of 
HRR could also lead to enhanced sensitivity towards proton 
versus photon irradiation. However, the development of phar-
macological agents directly targeting moieties of the HRR 
machinery has been largely unsuccessful so far. Nevertheless, 
several chemotherapeutic agents exist, which eventually affect 
HRR, e.g. by the downregulation of respective HRR- elements. 
For example, low dose exposure of lung adenocarcinoma cells 
to the histone deacetylase inhibitor SAHA (Vorinostat) down-
regulates Rad51 protein levels but not critical elements of NHEJ, 
and thereby specifically reduces HRR activity.54 Of note, DNA 
repair in SAHA- pretreated cells was in particular delayed after 
proton irradiation and much less so in response to photon irradi-
ation, and cellular pretreatment with SAHA also translated into 
enhanced radiosensitivity towards proton irradiation.30
Interestingly, SAHA- based radiosensitization was also inves-
tigated in response to different qualities of ionizing radiation 
(photon, low LET proton and high LET carbon irradiation) in 
lung carcinoma cells versus normal human fibroblasts.55 SAHA 
specifically sensitized tumor cells and less so normal fibroblasts, 
which is of interest towards an enhanced therapeutic window. 
Furthermore, these studies also demonstrated delayed DNA 
repair and most potent SAHA- based sensitization at low doses 
for proton irradiation.
Besides SAHA, other pharmaceutical agents in early develop-
mental stage exist, which directly or indirectly reduce HRR- 
activity. The inhibitor of the heat shock chaperone hsp90 
ganetespib counteracts irradiation- enhanced RAD51protein 
levels and thereby sensitizes lung adenocarcinoma cells for 
ionizing radiation.56 The Brc- abl tyrosine kinase inhibitor gleevec, 
which is used to treat chronic myelogenous leukemia (CML), 
also reduces RAD51protein levels and thereby sensitizes for irra-
diation.57 Likewise, reduced formation of the RAD51- BRCA2 
complex is also induced on cellular treatment with inhibitors of 
the hepatocyte growth factor receptor Mesenchymal- Epithelial 
Transition (MET). MET is overexpressed in multiple types of 
human tumors and inhibition of MET kinase activity also sensi-
tizes for ionizing radiation.58
Selective targeting of HRR even represents the mechanism of 
action for clinically applied chemotherapeutic agents and radio-
sensitizers, e.g. gemcitabine, when used in combination with 
photon radiotherapy.59 Thus, a reduced dose of proton radia-
tion might be sufficient when combined with HRR- co- targeting 
agents to achieve the same treatment outcome as when combined 
with classic radiotherapy.
On the other hand, inhibitors of NHEJ might sensitize more 
for photon than for proton irradiation. Indeed, the DNA- PKcs 
inhibitor NU7026 strongly delayed repair of photon- but not 
proton- induced DNA DSB damage and subsequently sensitized 
lung carcinoma and glioblastoma to a higher extent to photon 
than to proton irradiation.30 These results also indicate that 
HRR and not NHEJ is the primary repair machinery for proton- 
induced DNA DSBs.
The identification of immunosuppressive mechanisms and 
respective blocking immune checkpoint inhibitors boosted an 
immense level of basic, translational and clinical research at the 
interface of radiotherapy and immunology leading to prom-
ising clinical trials of radiotherapy in combination with immune 
checkpoint inhibitors.60 Radiotherapy has long been classified as 
immunosuppressive. However, preclinical studies with hypof-
ractionated regimens have revealed that increased doses of 
ionizing radiation induce potent anti tumor immune responses, 
and several strategies have been developed to heat- up the cancer 
immunity cycle and to increase irradiation- induced immuno-
genic cell death.61 Likewise, we also start to identify mechanisms 
on the molecular level how DNA damage drives the regulation of 
immune checkpoints.62,63 In order to follow this line of research 
there is a great need to explore how the different qualities of 
ionizing radiation interfere with immunogenic cell death and 
the cancer immunity cycle. For example, TREX1 is an endonu-
clease, degrades small DNA fragments and thereby downregu-
lates irradiation- induced immunogenic cell death (see above). 
TREX1 is upregulated in particular in response to single high 
doses of ionizing radiation, and thus, TREX1 inhibitors could be 
of great interest to stimulate immunogenic cell death in partic-
ular as part of a hypofractionated treatment regimen.64 However, 
due to the different qualities of proton irradiation- induced DNA 
damage and a differential requirement for HRR as major DNA 
repair mechanism, the expression of TREX1 might also be regu-
lated in a differential way and thereby influence immunogenic 
cell death in a differential way.
Recently, a novel inhibitor of the HRR- upstream- situated serine/
threonine- specific protein kinase ATR (AZD6738) was demon-
strated to sensitize for ionizing radiation in vitro and in vivo.65 
Interestingly, AZD6738 in combination with irradiation not 
only reduced clonogenicity, but also increased the amount of 
irradiation- induced cellular micronuclei. Thus, the ATR and 
other HR- oriented inhibitors could thereby not only increase 
hypersensitivity on the unicellular level but even increase immu-
nogenic cell death on the tumor level in response to proton 
irradiation.
However, most treatment combinations have only been investi-
gated with classic photon irradiation. It will be now important 
to perform both efficacy- and mechanistic- oriented studies 
with these clinically relevant agents in combination with proton 
radiotherapy. Eventually, these investigations could lead to the 
integration of biological parameters for patient’s stratification to 
either quality of ionizing radiation.
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